Dysplasia and Cancer in a Large Multicenter Cohort of Patients With Barrett’s Esophagus  Prateek Sharma, Gary W. Falk, Allan P. Weston, Dean Reker, Mark Johnston, Richard E. Sampliner  Clinical Gastroenterology and Hepatology  Volume 4, Issue 5, Pages 566-572 (May 2006) DOI: 10.1016/j.cgh.2006.03.001 Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 1 Progression to adenocarcinoma in patients with Barrett’s esophagus during follow-up. Twelve patients developed cancer during a mean follow-up of 4.12 years. The grades of dysplasia at baseline, during follow-up, and at the final endoscopy are also shown. The number of patients is shown in parentheses. Clinical Gastroenterology and Hepatology 2006 4, 566-572DOI: (10.1016/j.cgh.2006.03.001) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 2 Barrett’s esophagus and development of cancer: event distribution. Kaplan-Meier curve showing the percentage of patients free of esophageal adenocarcinoma during follow-up. There was a gradual decrease in the number of patients as the duration of follow-up increased. Clinical Gastroenterology and Hepatology 2006 4, 566-572DOI: (10.1016/j.cgh.2006.03.001) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 3 Even patients with nondysplastic Barrett’s esophagus progressed to HGD and cancer during follow-up. The number of patients is shown in parentheses. Clinical Gastroenterology and Hepatology 2006 4, 566-572DOI: (10.1016/j.cgh.2006.03.001) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 4 Outcome of patients with LGD during follow-up. The majority of the patients regressed to nondysplastic Barrett’s esophagus. Clinical Gastroenterology and Hepatology 2006 4, 566-572DOI: (10.1016/j.cgh.2006.03.001) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions